Related Experiment Video

Updated: Dec 21, 2025

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
03:07

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

650

Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2

Masato Takahashi1, Norikazu Masuda2, Reiki Nishimura3

  • 1National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan.

Cancer Medicine
|May 19, 2020
PubMed

Insights

Palbociclib plus letrozole demonstrated sustained efficacy and tolerability in Japanese women with advanced hormone receptor-positive breast cancer. Updated results show a median progression-free survival of 35.7 months, with manageable side effects.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer is a significant health concern.
  • Palbociclib, a cyclin-dependent kinases 4 and 6 inhibitor, is an established treatment for this condition.
  • First-line treatment options are crucial for improving patient outcomes.

Purpose of the Study:

  • To investigate the updated efficacy and safety of palbociclib plus letrozole in Japanese postmenopausal women with advanced breast cancer.
  • To assess long-term progression-free survival and response rates.
  • To evaluate the safety profile and impact on quality of life.

Main Methods:

  • An open-label, single-arm, Japanese phase 2 study.
  • 42 postmenopausal patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer received first-line palbociclib plus letrozole.
  • Updated efficacy and safety data were collected and analyzed with extended follow-up.

Main Results:

  • The 1-year progression-free survival rate was 75.6%.
  • Median progression-free survival was 35.7 months.
  • Objective response rate was 47.6%, and disease control rate was 85.7%.
  • Common adverse events included neutropenia (100%) and leukopenia (83%), generally manageable.
  • No clinically meaningful deterioration in quality of life was observed.

Conclusions:

  • Palbociclib plus letrozole demonstrated sustained efficacy and a tolerable safety profile in Japanese postmenopausal patients with advanced ER+/HER2- breast cancer.
  • The combination therapy offers a valuable first-line treatment option for this patient population.
  • Long-term follow-up confirms the benefits and safety of this treatment regimen.
Keywords:
Japaneseadvanced breast cancercyclin-dependent kinaseletrozolepalbociclib

More Related Videos

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs10:38

Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

Published on: December 16, 2022

2.6K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
580
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
7.5K